By Paul A. Bunn Jr., MD Posted: May 27, 2019 It is indeed an exciting time in lung cancer therapeutics, and we have reasons to be optimistic. To put these advances […] Read more

By Cornedine Jannette de Gooijer, MD; Maria Disselhorst, MD; and Paul Baas, MD, PhD Posted: May 27, 2019 Dr. Cornedine Jannette de Gooijer Until 2015, few changes occurred with respect to […] Read more

Posted: May 27, 2019 In March 2019, another successful Best of the World Lung Cancer Conference (BWLCC) was held in Lima, Peru. This was the fourth year in a row that […] Read more

Posted: May 27, 2019 Nasser H. Hanna, MD, is the Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research at Indiana University School of Medicine, and he specializes […] Read more

By Alice Shaw, MD, PhD Posted: May 27, 2019 On November 2, 2018, lorlatinib, a potent and central nervous system (CNS)–penetrant next-generation ALK/ROS1 inhibitor, was granted accelerated approval by the U.S. […] Read more

By Anne-Claire Toffart, MD, PhD, and Jean-François Timsit, MD, PhD Posted: April 1, 2019 Dr. Anne-Claire Toffart Survival rates for patients with lung cancer who were admitted into the intensive care […] Read more

Posted: April 1, 2019 Why TMB Should Be Assessed in Patients with Advanced NSCLC By Fabrice Barlesi, MD, PhD Dr. Fabrice Barlesi Immune checkpoint inhibitors, especially PD-1 and PD-L1 inhibitors, have […] Read more

By Russell Bahar, Bsc and Elliot Wakeam, MD, MPH Posted: April 1, 2019 IN REFERENCE TO: Serna-Gallegos DR, et al Effects of time from completed clinical staging to surgery: Does it […] Read more

By Michael MacManus, MD, FRANZCR, and Tim Akhurst, MD, FRACP Posted: March 1, 2019  Dr. Michael MacManus 18F-FDG PET/CT scans portray living biology and are indispensable in thoracic oncologic evaluations, […] Read more

By Andrew R. Haas, MD, PhD Posted: October 2018 Lung cancer remains the leading global cause of cancer-related mortality.1 Due to the lack of symptoms at the time early-stage disease […] Read more